TY - JOUR
T1 - Gln27→Gluβ2-adrenergic receptor polymorphism in heart failure patients
T2 - Differential clinical and oxidative response to carvedilol
AU - Troncoso, Rodrigo
AU - Moraga, Francisco
AU - Chiong, Mario
AU - Roldán, Juan
AU - Bravo, Roberto
AU - Valenzuela, Rodrigo
AU - Díaz-Araya, Guillermo
AU - Del Campo, Andrea
AU - Sanhueza, Carlos
AU - Rodriguez, Andrea
AU - Vukasovic, José Luis
AU - Mellado, Rosemarie
AU - Greig, Douglas
AU - Castro, Pablo F.
AU - Lavandero, Sergio
PY - 2009/5
Y1 - 2009/5
N2 - We investigated the clinical response of chronic heart failure patients with β2-adrenergic receptor Gln27→Glu polymorphism treated for 6 months with carvedilol, a α/β-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27→Gluβ2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu 27β2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27β2- adrenergic receptor variant.
AB - We investigated the clinical response of chronic heart failure patients with β2-adrenergic receptor Gln27→Glu polymorphism treated for 6 months with carvedilol, a α/β-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27→Gluβ2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu 27β2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27β2- adrenergic receptor variant.
UR - http://www.scopus.com/inward/record.url?scp=64549105750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64549105750&partnerID=8YFLogxK
U2 - 10.1111/j.1742-7843.2008.00370.x
DO - 10.1111/j.1742-7843.2008.00370.x
M3 - Article
C2 - 19422106
AN - SCOPUS:64549105750
SN - 1742-7835
VL - 104
SP - 374
EP - 378
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
IS - 5
ER -